These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7686262)

  • 1. Physical methods for the detection of carcinogen-DNA adducts in humans.
    Weston A
    Mutat Res; 1993 Jul; 288(1):19-29. PubMed ID: 7686262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA: applications for detection of xenobiotics in biological samples.
    Poirier MC
    Mutat Res; 1993 Jul; 288(1):31-8. PubMed ID: 7686263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 32P-postlabelling and mass spectrometric methods for analysis of bulky, polyaromatic carcinogen-DNA adducts in humans.
    Talaska G; Roh JH; Getek T
    J Chromatogr; 1992 Sep; 580(1-2):293-323. PubMed ID: 1400827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined micropreparative techniques with synchronous fluorescence spectroscopy or 32P-postlabelling assay for carcinogen-DNA adduct determination.
    Shields PG; Kato S; Bowman ED; Petruzzelli S; Cooper DP; Povey AC; Weston A
    IARC Sci Publ; 1993; (124):243-54. PubMed ID: 8225491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA adduct determination in humans.
    Poirier MC; Weston A
    Prog Clin Biol Res; 1991; 372():205-18. PubMed ID: 1956919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 32P-postlabeling assay for carcinogen-DNA adducts and other dna modifications.
    Randerath K; Randerath E
    J UOEH; 1989 Mar; 11 Suppl():368-86. PubMed ID: 2664950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinogen macromolecular adducts and their measurement.
    Poirier MC; Santella RM; Weston A
    Carcinogenesis; 2000 Mar; 21(3):353-9. PubMed ID: 10688855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinogen-DNA adducts in exfoliated urothelial cells: techniques for noninvasive human monitoring.
    Talaska G; Schamer M; Skipper P; Tannenbaum S; Caporaso N; Kadlubar F; Bartsch H; Vineis P
    Environ Health Perspect; 1993 Mar; 99():289-91. PubMed ID: 8319646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantages and limitations of laboratory methods for measurement of carcinogen-DNA adducts for epidemiological studies.
    Kaderlik RK; Lin DX; Lang NP; Kadlubar FF
    Toxicol Lett; 1992 Dec; 64-65 Spec No():469-75. PubMed ID: 1471199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of DNA adducts at the DNA sequence level by ligation-mediated PCR.
    Pfeifer GP; Drouin R; Holmquist GP
    Mutat Res; 1993 Jul; 288(1):39-46. PubMed ID: 7686264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and characterization of carcinogen-DNA adducts in exfoliated urothelial cells from 4-aminobiphenyl-treated dogs by 32P-postlabelling and subsequent thin-layer and high-pressure liquid chromatography.
    Talaska G; Dooley KL; Kadlubar FF
    Carcinogenesis; 1990 Apr; 11(4):639-46. PubMed ID: 2323002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring carcinogen actions on DNA by 32P-postlabeling.
    Randerath K; Randerath E
    Princess Takamatsu Symp; 1990; 21():317-28. PubMed ID: 2134685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human exposure monitoring, dosimetry, and cancer risk assessment: the use of antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA.
    Poirier MC
    Drug Metab Rev; 1994; 26(1-2):87-109. PubMed ID: 8082583
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection and characterization of DNA adducts at the femtomole level by desorption ionization mass spectrometry.
    Lay JO; Chiarelli MP; Bryant MS; Nelson RW
    Environ Health Perspect; 1993 Mar; 99():191-3. PubMed ID: 8319622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel uses of mass spectrometry in studies of adducts of alkylating agents with nucleic acids and proteins.
    Farmer PB; Lamb J; Lawley PD
    IARC Sci Publ; 1988; (89):347-55. PubMed ID: 3198219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of HPLC in the 32P-postlabeling assay.
    Gorelick NJ
    Mutat Res; 1993 Jul; 288(1):5-18. PubMed ID: 7686266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for detecting DNA damaging agents in humans. Summary: adducts.
    Lohman PH
    IARC Sci Publ; 1988; (89):13-22. PubMed ID: 3198196
    [No Abstract]   [Full Text] [Related]  

  • 18. DNA dosimetry following carcinogen exposure using accelerator mass spectrometry and 32P-postlabeling.
    Felton JS; Turteltaub KW; Gledhill BL; Vogel JS; Buonarati MH; Davis JC
    Prog Clin Biol Res; 1991; 372():243-53. PubMed ID: 1956922
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity.
    Talaska G; Schamer M; Skipper P; Tannenbaum S; Caporaso N; Unruh L; Kadlubar FF; Bartsch H; Malaveille C; Vineis P
    Cancer Epidemiol Biomarkers Prev; 1991; 1(1):61-6. PubMed ID: 1845172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA.
    Turteltaub KW; Felton JS; Gledhill BL; Vogel JS; Southon JR; Caffee MW; Finkel RC; Nelson DE; Proctor ID; Davis JC
    Proc Natl Acad Sci U S A; 1990 Jul; 87(14):5288-92. PubMed ID: 2371271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.